Platelet production proceeds independently of the intrinsic and extrinsic apoptosis pathways

Area of Science:

• Hematology
• Molecular Biology
• Cancer Therapy

Background:

• BH3 mimetic drugs targeting BCL-2 family proteins offer new cancer therapy avenues.
• Navitoclax trials show promise but dose-limiting thrombocytopenia due to BCL-XL inhibition in platelets.
• BCL-XL is crucial for platelet survival, raising questions about megakaryocyte apoptosis in platelet shedding.

Purpose of the Study:

• To investigate the role of apoptosis in platelet biogenesis.
• To determine if megakaryocytes utilize extrinsic or intrinsic apoptosis pathways for platelet production.
• To assess the necessity of apoptosis for thrombopoiesis.

Main Methods:

• Generated mice with megakaryocyte-specific deletions of Caspase-8 (extrinsic apoptosis) and BAK/BAX (intrinsic apoptosis).
• Activated the Fas ligand-inducible extrinsic apoptosis pathway in megakaryocytes.
• Observed the effects of combined Caspase-8/BAK/BAX loss on thrombopoiesis and megakaryocyte survival during viral infection.

Main Results:

• Fas activation in megakaryocytes triggers Caspase-8-mediated cell death, not platelet production.
• Combined loss of Caspase-8, BAK, and BAX does not impede thrombopoiesis.
• Megakaryocyte apoptosis is dispensable for platelet biogenesis, and its absence can protect against viral-induced death.

Conclusions:

• Platelet biogenesis does not require megakaryocyte apoptosis.
• Megakaryocytes possess functional extrinsic and intrinsic apoptosis pathways that are not coupled to platelet production.
• Targeting BCL-XL in cancer therapy may not impact platelet production, but its role in platelet survival warrants careful consideration.